ADC Landscape
Merck / Daiichi
B7-H3 · Small-cell lung cancer
Phase 3Antibody–Drug Conjugates
Target
B7-H3
Payload
Deruxtecan (DXd)
Payload class
Topo-I inhibitor
Linker
Cleavable tetrapeptide
Indication
Small-cell lung cancer
Phase
Phase 3
Partner
Merck ($22B alliance)
Overview
Part of Merck's ~$22B Daiichi alliance for three DXd ADCs. B7-H3 is broadly expressed across tumors — a high-value emerging target. SCLC data has been a standout.
Technology
Merck / Daiichi works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.